





# Molecular Mechanisms Inform New Therapies for Pulmonary Arterial Hypertension



# PA Hypertension is Characterized by Vessel Loss, Occlusive Proliferation of Vascular Cells, and Inflammation




# Mutation or Reduced Function of BMPR2 is Observed in Pulmonary Arterial Hypertension (PAH):




*Mutation in BMPR2*  
in 70% familial PAH and  
20% of sporadic IPAH:

*Reduced BMPR2 function in all forms of PAH*

# BMPR2 Maintains Vascular Homeostasis



# Loss of BMPR2 Promotes Endothelial-Mesenchymal Transition




Rachel Hopper  
Circulation, 2016

Endothelial  
apoptosis


Loss of EC genes  
gain of SMC genes

Mesenchymal-SMC  
phenotype



Inability to suppress SMC proliferation  
Reduced barrier function  
Compromised anti-inflammatory properties




# Mechanism of Endothelial Mesenchymal Transition in PAH




# Loss of BMPR2 in Smooth Muscle Cells from PAH Patients Increases Proliferation via Aldehyde Dehydrogenase ALDH1A3



Dan Li




# In PAH, Nuclear ALDH1A3 is Increased in PA SMC






# Reducing ALDH1A3 (si) Suppresses PAH Smooth Muscle Cell Proliferation




# SMC-*Aldh1a3*<sup>-/-</sup> KO Mice Do Not Develop Hypoxic PH




SM22 *Cre*-*Aldh1a3*<sup>-/-</sup> male mice. N=8; \*\*P<0.01 vs. KO in Hx, and ##P<0.01 vs. WT, Room Air, one-way ANOVA and Bonferroni's

# Deleting *Aldh1a3* in SMC Eliminates PH and Abnormal Muscularization of PAs in Hypoxia




WT



SM22 *Aldh1a3*<sup>-/-</sup>


# Loss of BMPR2 Increases ALDH1A3 to Acetylate Histones, Open Chromatin and Regulate Genes Required for Proliferation



# Loss of BMPR2 Underlies EC Dysfunction, SMC Proliferation and Can Fuel Chronic Inflammation


Impairs arterial regeneration of and causes EC transformation to SM-like cells

Enhances SMC proliferation via ALDH1A3




Enhances recruitment of ABNORMAL inflammatory cells to injured PAs causing further structural damage

# IPAH Neutrophils (PMN) Have Increased Elastase and Release More Active Elastase in Response to Stimulation




## ELASTASE Activity in Response to IL8 (% Total)



Shalina Taylor

# Circulating Elastase is Increased & Inhibitor Elafin is Reduced in Patients with All Forms of PA Hypertension (Zamanian et al)




CHD Congenital Heart    CTD Connective Tissue    D/T Drugs and Toxins  
IPAH Idiopathic PAH    PPH Portopulmonary PAH

# PAH Neutrophils Show a type I Interferon Response Related to Elevated Endogenous Retroviral Elements (HERVs)


Gene Name	Log 2 Fold change
IFIT1	~4.5
EIF2AK2 (PKR)	~4.0
DDX58 (RIG-I)	~3.5
UBE2E1	~2.5
IFNAR1	~2.0
IFNGR2	~1.5
EIF4E3	~1.0
IFNAR2	~0.5



HERV-K envelope



HERV-K dUTPase



*Receptors and effectors of interferon type 1 response*

N=6; \*p<0.05, \*\*p<0.01




# Endogenous Retrovirus HERV-K

- Endogenous retrovirus sequences are stored in our genome as remnants of ancestral retroviral infections.

*They are not infectious but their products dUTPase and envelope proteins can induce a chronic innate immune response.*

- Abnormal amplification of HERV-K has been linked to autoimmunity and cancer, and PAH (Saito et al, Circulation, 2016)




# HERV-K dUTPase Can Induce Elastase in Neutrophil Line



# Loss of BMPR2 Underlies EC Dysfunction, SMC Proliferation and Can Fuel Chronic Inflammation

Impairs regeneration of small vessels after injury and causes EC transformation to SM-like cells

Enhances SMC proliferation via ALDH1A3



Enhances recruitment of neutrophils with elevated elastase to PAs


Impairs assembly of elastic fibers

# Loss or Mutation of BMPR2 Reduces Elastic Fiber Deposition in Cells from PAH Patients



Nancy Tojais

ATVB, 2017




Vehicle

BMP4



TGFB

Elastin  
% Fluorescence



\* vs. Vehicle; # vs. Donor

# Degradation of Elastin Precedes & Accompanies Progressive Pulmonary Vascular Pathology




- Loss of elastin:
- Increases vascular stiffness
  - Promotes SMC proliferation & obliterative changes
  - Leads to loss of the distal microcirculation
  - Breakdown products of elastin are pro-inflammatory

## Ideal PAH Therapies Activate BMPR2 and Suppress Inflammation


**FK506:** Identified on a high throughput screen of 4500 compounds, as top activator of BMPR2  
(*Spiekerkoetter, JCI, 2013*)

**Elafin:** A recombinant endogenous elastase inhibitor found by serendipity to activate BMPR2  
(*Nickel, AJRCCM, 2015*)

# Immunosuppressant Tacrolimus (FK506) and Elastase Inhibitor Elafin Amplify a Weak BMPR2 Signal




# IPA H PAEC and iPSC-EC Respond to Elafin and FK506 by Similar Improvement in Angiogenesis







# High-Throughput Drug Screen in to Find a Drug to Repurpose to Reverse iPSC Derived Vascular Cell Dysfunction



# Drug Screening: Tyrosine Kinase Inhibitor SG1296 Improves PAH EC Survival and Suppresses PA SMC Proliferation




iPSC-EC Survival Improved



SMC Proliferation Reduced

# Using Bioinformatics to Find Additional Rx

Identify bait compound  
TKI AG1296



LINCS DATA BASE  
AG1296  
expression profile  
across multiple cells



Bait signature



PAH gene signature

GEO database

Lung: 32 PAH, 28 Healthy  
PBMC: 52 PAH, 57 Healthy

Bait-signature



Anti-PAH signature



Specific pathway  
targeted by the TKI




Predict new drug with  
similar signature


PAH signature

Anti signature

# Bioinformatics Informs Drugs that Can Prevent or Cause PAH



# BMPR2 is Elevated and Packaged in Exosomes and Released by Cells Under Stress




David Marciano




# Exosomes as Therapy for Pulmonary Hypertension

Make  
exosomes  
cell particles




BMPR2 enriched exosomes  
reverse PAH EC and SMC dysfunction





Endo  
Cells

Smooth  
Muscle  
Cells



\*\*p<0.01, \*\*\*p<0.001, vs. siC, Normoxia

# Administration of BMPR2 via Endothelial Exosomes Prevents PH in Transgenic Mice with EC Lacking BMPR2



\*p<0.05, \*\*p<0.01 vs. KO, Hypoxia

## Conclusions

- Reduced BMPR2 induces adverse effects related to PAH
  - (i) transformation of endothelial to smooth muscle like cells
  - (i) proliferation of smooth muscle cells,
  - (iii) recruitment of elastin degrading neutrophils
  - (iv) impaired elastic fiber assembly
- Therapies that restore BMPR2 function have promise in reversing PAH.



# Acknowledgement

Funding:

NIH-NHLBI,  
CMREF, AHA,

Rachel Hopper

Dan Li

Shalina Taylor

Nancy Tojais

Mingxia Gu

Nils Nickel

Edda Spiekerkoetter

Lingli Wang,

Aiqin Quo

## Collaborations-Stanford

Joe Wu

Michael Snyder

Purvesh Khatri

Roham Zamanian

Justin Vincent, Yan Zhuge

James Chappell,

Michele Donato

Patricia del Rosario

## PHBI Network

U. Of Keil O. Wiedow U of Kiel



Joe Wu MD PhD  
CVI Director



Purvesh Khatri, PhD  
Assoc Professor  
Computational Biology



Silin Sa  
Am J Resp  
Crit Care Med  
April 2017



Mingxia Gu  
Cell Stem Cell  
April 2017



Michael Snyder, PhD  
Professor of Genetics



Shai Mao